Research news - the latest biotech news from Labiotech.eu

Can the microbiome help the fight against infections?

Jim Cornall — Tue, 25 Jul 2023 09:30:00 +0000

Animals and humans coexist with a vast array of microorganisms known as the microbiome, forming a relationship that can range from mutually beneficial to pathogenic. To safeguard against harmful pathogens and maintain the presence of beneficial microorganisms, animals have evolved various defenses.One is small antimicrobial peptides (AMPs), small peptides that combat invading microbes. AMPs are […]

The post Can the microbiome help the fight against infections? appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

How AI is shaping clinical research and trials

Willow Shah-Neville — Fri, 21 Jul 2023 10:31:56 +0000

Artificial intelligence (AI) is everywhere at the minute, seemingly being used in some capacity in almost every professional industry, including clinical research and trials. In fact, it is fair to say that AI has taken the biotech industry by storm, and the hype surrounding it has led to numerous AI startup companies coming onto the […]

The post How AI is shaping clinical research and trials appeared first on Labiotech.eu.

CatalYm shows importance of GDF-15 in tumor immunotherapy resistance

Jim Cornall — Thu, 20 Jul 2023 17:00:00 +0000

CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed […]

The post CatalYm shows importance of GDF-15 in tumor immunotherapy resistance appeared first on Labiotech.eu.

Novel bacterial communication system could help take on antimicrobial resistance

Jim Cornall — Wed, 19 Jul 2023 10:30:00 +0000

A new stress signaling system enables bacteria cells to adapt and protect themselves against the immune system and certain antibiotics. The discovery was made by researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with Singapore Centre for Environmental […]

The post Novel bacterial communication system could help take on antimicrobial resistance appeared first on Labiotech.eu.

Life saved: AI discovers existing drug works for rare disease

Jim Cornall — Fri, 14 Jul 2023 09:45:00 +0000

A patient’s life was saved after researchers at the University of Pennsylvania, Castleman Disease Collaborative Network, Medidata, and Every Cure, used artificial intelligence to use an existing drug to treat idiopathic multicentric Castleman disease (iMCD). Every Cure and its partners are developing medical databases and AI algorithms to unlock new uses for existing medicines across […]

The post Life saved: AI discovers existing drug works for rare disease appeared first on Labiotech.eu.

Immune memory research could lead to next generation of epigenetic drugs

Jim Cornall — Tue, 11 Jul 2023 10:31:34 +0000

A team of researchers has discovered that the memory of the immune system relies on characteristic epigenetic features and a specific 3D arrangement of the DNA in the nucleus of memory cells, allowing for a fast activation of these cells. These features are altered in chronic inflammation diseases like asthma and could be important in […]

The post Immune memory research could lead to next generation of epigenetic drugs appeared first on Labiotech.eu.

Existing cancer drug could be repurposed to fight certain aggressive cancers

Jim Cornall — Mon, 10 Jul 2023 15:00:00 +0000

A team of scientists led by Nanyang Technological University, Singapore (NTU Singapore) has found that an existing cancer drug could be repurposed to target a subset of cancers that currently lack targeted treatment options and is often associated with poor outcomes.This subset of cancers makes up 15% of all cancers and is especially prevalent in […]

The post Existing cancer drug could be repurposed to fight certain aggressive cancers appeared first on Labiotech.eu.

Swedish researchers look to peptides to destroy viruses

Jim Cornall — Fri, 07 Jul 2023 08:41:11 +0000

A new study from Sweden shows how a type of peptide from a lactic acid bacterium destroys viruses, including coronavirus. The findings have resulted in a Swedish patent, with an international patent pending. “We’re hoping for a quick turnaround to allow this discovery to be utilised in antiviral treatments and as a complement to vaccine,” […]

The post Swedish researchers look to peptides to destroy viruses appeared first on Labiotech.eu.

Six biotech spinouts you should watch out for this year

Roohi Mariam Peter — Tue, 04 Jul 2023 11:47:12 +0000

Academic spinouts are companies that are typically formed from research taking place at academic institutions and are sometimes launched and owned by the university. A means to turn research into products of commercial value, the biotech industry has witnessed quite a few spinouts develop from research projects over the years. In the U.K. alone, the […]

The post Six biotech spinouts you should watch out for this year appeared first on Labiotech.eu.

New drug helps prostate cancer patients

Jim Cornall — Tue, 04 Jul 2023 09:13:03 +0000

Researchers at the Paul Scherrer Institute (PSI) in Switzerland have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug is now being tested on patients in the PROGNOSTICS project. A research consortium consisting of the PSI, the University Hospital Basel and ETH Zurich is receiving CHF […]

The post New drug helps prostate cancer patients appeared first on Labiotech.eu.

New osteoarthritis treatment for horses could work for humans

Jim Cornall — Mon, 03 Jul 2023 14:28:20 +0000

For the first time, an intervention that seems to slow down osteoarthritis (OA) progression has been presented. In a clinical study from the Swedish University of Agricultural Sciences and the University of Gothenburg, OA horses that received a novel drug treatment became completely free from lameness, with a simultaneous impediment of the joint tissue degradation. […]

The post New osteoarthritis treatment for horses could work for humans appeared first on Labiotech.eu.

Beyond Biotech podcast 52: Antiphospholipid syndrome

Jim Cornall — Fri, 30 Jun 2023 09:02:56 +0000

June is Antiphospholipid Syndrome (APS) Awareness Month. APS is a rare autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. There are two known forms. APS may occur in people with systemic lupus erythematosus, other autoimmune disease, or in otherwise healthy […]

The post Beyond Biotech podcast 52: Antiphospholipid syndrome appeared first on Labiotech.eu.

Virus tracking could be key to kidney transplant patients’ drug choices

External Contributor — Fri, 30 Jun 2023 08:32:49 +0000

By Dr Gregor Bond More than 15,000 Europeans undergo kidney transplants on average each year, and while medical advances have helped many recipients enjoy healthy lives, the risks of organ rejection and infection remain huge challenges. With each transplant, success depends on using carefully balanced doses of immuno-suppressive drugs to reduce the risk of infection […]

The post Virus tracking could be key to kidney transplant patients’ drug choices appeared first on Labiotech.eu.

Small particles will deliver TB drugs to the lungs in the future

Jim Cornall — Wed, 28 Jun 2023 15:15:00 +0000

Treatment of the dangerous infectious disease tuberculosis faces the challenge of pathogens frequently being resistant to several common antibiotics. Researchers at Karlsruhe Institute of Technology (KIT) in Germany have developed nanoparticles to deliver new antibiotics directly to the lungs in the future. Surfactants ensure that the highly fat-soluble antibiotics disperse very finely in water and […]

The post Small particles will deliver TB drugs to the lungs in the future appeared first on Labiotech.eu.

New platform cuts time engineering and selecting genome editors

Jim Cornall — Wed, 28 Jun 2023 13:41:44 +0000

A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed a new way to break through the current limited throughput in optimizing precise genome editors at scale, engineer hundreds of base editor variants in parallel instead of current one-by-one testing, and informing users of the most suitable ones […]

The post New platform cuts time engineering and selecting genome editors appeared first on Labiotech.eu.

Breakthrough treatment for skin infections?

Jim Cornall — Fri, 23 Jun 2023 09:45:00 +0000

A research team led by Kelvin Yeung from the Department of Orthopaedics and Traumatology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has designed a new microneedle patch that provides an effective non-antibiotic approach for the treatment of skin infections. The design engineered with ultrasound-responsive zinc-based metal-organic framework (MOF) […]

The post Breakthrough treatment for skin infections? appeared first on Labiotech.eu.

Ovarian cancer study finds key genes for potential treatments

Jim Cornall — Thu, 22 Jun 2023 09:13:36 +0000

New study is increasing knowledge of why some women with the most lethal form of ovarian cancer respond much better to treatment than others. Researchers at Imperial College London in the U.K. have confirmed that the tumors of some women with high-grade serious ovarian cancer (HGSOC) contain a type of lymphoid tissue – known as […]

The post Ovarian cancer study finds key genes for potential treatments appeared first on Labiotech.eu.

Key regulator of COVID viral receptor may be new drug target

Jim Cornall — Fri, 16 Jun 2023 08:45:00 +0000

Entry of the SARS-CoV-2 virus into human tissues depends on the activity of a host gene that regulates production of a key viral receptor, according to a study published in the open access journal PLOS Biology by Madison Strine and Craig Wilen of Yale University, U.S., and colleagues. The finding provides important new information on […]

The post Key regulator of COVID viral receptor may be new drug target appeared first on Labiotech.eu.

Researchers say open-source collaboration is ‘fundamental’

Jim Cornall — Thu, 15 Jun 2023 10:57:44 +0000

New Seqera Labs data have revealed that 72% of research scientists believe open-source collaboration and workflow management is now “fundamental” to the work they do. The data published by Seqera Labs, a provider of secure data orchestration software, brings together the views of 500 researchers and scientists who use open-source scientific workflow platforms for their […]

The post Researchers say open-source collaboration is ‘fundamental’ appeared first on Labiotech.eu.

IOME Bio claims breakthrough in cancer research

Jim Cornall — Thu, 15 Jun 2023 10:28:35 +0000

IOME Bio, a French seed stage biotechnology company focused on overcoming tumor resistance to immune checkpoint inhibition, has published its foundational research by founders Arlene Sharpe and Dennis Kasper in Nature. The company said its work reveals unique insights into the critical importance of the RGMb/PD-L2 pathway in immunotherapy resistance and further strengthens the significance […]

The post IOME Bio claims breakthrough in cancer research appeared first on Labiotech.eu.